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Clinical Research faces perhaps a certain grain of confu-
sion. Often, it is mistakenly reduced to case report. Cave-
ats of even greater risks may be hidden in the secrets of
patents and interests of manufacturers covertly promoting
their products. Thus, a book clearly stating what a clinical
trial is, well located within the scientific frame, appears as
a significant contribution enhancing the importance and
complexity of XXIst Century human health.
The book is preceded by two editions (1981 and 1985)
and well backed by the experience and prestige of its
authors. Clinical Research, a branch of Applied Research,
finds in clinical trials the most definitive tool for evalua-
tion of its actual applicability. The book is divided in 19
chapters, each setting up unequivocally the Fundamental
Point to be treated, as for example the introductory Chap-
ter 1: A properly planned and executed clinical trial is a power-
ful experimental technique for assessing the effectiveness of an
intervention. A clinical trial compares the effect and value of
intervention(s) against a control in human beings. Inter-
vention refers either to a drug, a procedure or a technolog-
ical device, thus implying that biomedical engineering
scientists and professionals might be involved in it. Clini-
cal Research always presents early stages where the labora-
tory work is mandatory. This book emphasizes the
concept all along, so placing the clinical trial in its proper
hierarchical perspective. There is laboratory work during
drug, device and/or procedure development, animal stud-
ies and early tests in small number of human beings. Case
reports, typical of the hospital, find their place as a warn-
ing of adverse effects or as a flag of an unexpected benefi-
cial effect.
In Chapter 2 the authors emphasize that a clinical trial
must have a primary question. It should be carefully
selected, as any subsidiary question must be, too. Other-
wise, the investigators may lose the track. Chapter 3 deals
with the study population, underlying the importance of
unambiguous eligibility criteria, the latter having a direct
influence on the recruitment of participants and, thus, on
the final number involved in the project (which may end
up with not enough data). Chapter 4 outlines the basic
study design; it stresses the demand of a control group and
the need of randomization for assigning participants to
control and intervention groups.
An extremely important subject is the randomization
process, essential to avoid any possible bias (Chapter 5).
Several forms are presented: simple, blocked and strati-
fied. More elaborate procedures make use of adaptive
methods. There are examples and an appendix with an
algorithm of general applicability. Bias (a systematic
error) is one of the main concerns; thus, a double-blind
design is essential (Chapter 6). Chapter 7, Sample Size,
addresses the question of how many subjects is enough.
The trial must have sufficient statistical power to detect
differences between groups. Therefore, calculation of sam-
ple size with provision for adequate levels of significance
is essential. Several situations with their respective exam-
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ples are presented making of this pages an invaluable tool.
Unfortunately, several equations have been printed in
such a way that there is confusion on whether some
parameters are factors or exponents.
Baseline refers to the status of participants before the start
of the intervention (Chapter 8), while Chapter 9 deals
with the recruitment of participants. The latter depends
on developing a careful plan with multiple strategies.
Chapter 10 enters into data collection and quality control,
wisely underlining that no study can be better than the
quality of its data. Monitoring and even auditing are thus
necessary. The history of new medical interventions
abounds in sad experiences. Hence, adverse effects, if any
at all, must be searched and assessed. Chapter 11 clearly
probes into this complex aspect. Sadly, perhaps due to
sheer enthusiasm (and I do no want to hint possible com-
mercial interests because the idea alone crosses a risky
line), often it has played a secondary role in clinical trials,
as stated by the authors.
Chapter 12, by Michelle J. Naughton and Sally A. Shu-
maker, catches the assessment of health-related quality of
life, that is, trying to elucidate if the intervention
improved, say, physical, psychological and social func-
tioning, perception of well-being and health status, per-
sonal productivity, sexual life, sleep disturbances and
other parameters. Not an easy task, indeed, although in
certain extreme situations (as when life is supported by
mechanical means and conscience is no longer present)
may lead into deep controversies.
The remaining seven chapters deal, respectively, with par-
ticipant adherence to the program, survival analysis, mon-
itoring response variables (37 pages), issues in data
analysis (38 pages full of statistical considerations), clo-
seout (that is, how to properly terminate the study),
reporting and interpreting of results (one of the most dif-
ficult steps because recommendations will be produced
that may end up in massive use of the intervention), and
finally a chapter devoted to multicenter trials.
The book provides an exceedingly good collection of ref-
erences so that the interested reader can deepen in a par-
ticular subject. All in all, I would highly recommend it, to
the physician, basic investigator and biomedical engineer.
For the beginner, instead, it may be a little hard for some
parts require good knowledge of statistics. It is no doubt
excellent material for a course.Page 2 of 2
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